NO20045699L - Bisindolyl-maleimidderivater som kinaseinhibitorer - Google Patents
Bisindolyl-maleimidderivater som kinaseinhibitorerInfo
- Publication number
- NO20045699L NO20045699L NO20045699A NO20045699A NO20045699L NO 20045699 L NO20045699 L NO 20045699L NO 20045699 A NO20045699 A NO 20045699A NO 20045699 A NO20045699 A NO 20045699A NO 20045699 L NO20045699 L NO 20045699L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- kinase inhibitors
- kinase
- bisindolyl
- methods
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 150000003924 bisindolylmaleimides Chemical class 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- DXGTUUQHTDOFFQ-UHFFFAOYSA-N [N].C1=CC=C2NC=CC2=C1 Chemical group [N].C1=CC=C2NC=CC2=C1 DXGTUUQHTDOFFQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940127263 dual kinase inhibitor Drugs 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003236 pyrrolines Chemical class 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38593502P | 2002-06-05 | 2002-06-05 | |
| PCT/US2003/017569 WO2003104222A1 (en) | 2002-06-05 | 2003-06-04 | Bisindolyl-maleimid derivatives as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045699L true NO20045699L (no) | 2005-01-28 |
Family
ID=29736126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045699A NO20045699L (no) | 2002-06-05 | 2004-12-29 | Bisindolyl-maleimidderivater som kinaseinhibitorer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6987110B2 (ja) |
| EP (1) | EP1513830A1 (ja) |
| JP (1) | JP2005531609A (ja) |
| KR (1) | KR20050008787A (ja) |
| CN (1) | CN1671694A (ja) |
| AU (1) | AU2003238874A1 (ja) |
| BR (1) | BR0311821A (ja) |
| CA (1) | CA2488602A1 (ja) |
| CR (1) | CR7606A (ja) |
| IL (1) | IL165515A0 (ja) |
| MX (1) | MXPA04012188A (ja) |
| NO (1) | NO20045699L (ja) |
| RU (1) | RU2004135382A (ja) |
| WO (1) | WO2003104222A1 (ja) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20031594A3 (cs) | 2000-12-08 | 2004-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrrolinové sloučeniny substituované indazolylovou skupinou jako inhibitory kinázy |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| JP2005529918A (ja) * | 2002-05-08 | 2005-10-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換されたピロリンキナーゼ阻害剤 |
| AU2003240517A1 (en) * | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
| CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| AU2002951253A0 (en) * | 2002-09-06 | 2002-09-19 | Medvet Science Pty. Ltd. | A method of modulating cellular activity |
| CA2520590A1 (en) * | 2003-03-27 | 2004-11-04 | Janssen Pharmaceutica, N.V. | Substituted pyrroline kinase inhibitors |
| US7439363B2 (en) * | 2003-06-13 | 2008-10-21 | Janssen Parmaceutica N.V. | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors |
| WO2005083105A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b) |
| WO2005095983A1 (en) * | 2004-03-04 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg) |
| RU2413511C2 (ru) * | 2004-04-08 | 2011-03-10 | Новартис Аг | Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата |
| CA2560311A1 (en) * | 2004-04-08 | 2005-10-20 | Novartis Ag | Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection |
| CA2567377A1 (en) * | 2004-05-21 | 2006-03-09 | The Texas A & M University System | Inhibition of atherosclerosis by diindolylmethane analogs |
| EP1662259A1 (en) * | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| ES2400916T3 (es) * | 2005-06-08 | 2013-04-15 | Janssen Biotech, Inc. | Una terapia celular para degeneración ocular |
| JP2009501172A (ja) | 2005-07-11 | 2009-01-15 | ノバルティス アクチエンゲゼルシャフト | インドリルマレイミド誘導体 |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| CA2624378A1 (en) * | 2005-09-29 | 2007-04-12 | Janssen Pharmaceutica N.V. | Macroheterocylic compounds as kinase inhibitors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2017355A4 (en) * | 2006-04-25 | 2010-01-06 | Univ Kyushu Nat Univ Corp | ASSOCIATED WITH ARTERIOSCLEROSIS DISEASE AND USE THEREOF |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2008063278A (ja) * | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| CA3207103A1 (en) | 2007-07-31 | 2009-02-05 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to pancreatic endocrine |
| ATE523585T1 (de) * | 2007-11-27 | 2011-09-15 | Lifescan Inc | Differenzierung menschlicher embryonaler stammzellen |
| FR2927075A1 (fr) * | 2008-02-04 | 2009-08-07 | Centre Nat Rech Scient | Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes |
| RU2551772C2 (ru) | 2008-02-21 | 2015-05-27 | Сентокор Орто Байотек Инк. | Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток |
| US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| JP2011526784A (ja) * | 2008-06-30 | 2011-10-20 | セントコア・オーソ・バイオテツク・インコーポレーテツド | 多能性幹細胞の分化 |
| BRPI0914116A2 (pt) | 2008-06-30 | 2019-09-17 | Centocor Ortho Biotech Inc | diferenciação de células-tronco pluripotentes |
| US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
| CN107435038B (zh) * | 2008-10-31 | 2021-07-09 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
| RU2522001C2 (ru) | 2008-10-31 | 2014-07-10 | Сентокор Орто Байотек Инк. | Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток |
| CA2744227C (en) * | 2008-11-20 | 2018-10-02 | Centocor Ortho Biotech Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| JP2012509085A (ja) | 2008-11-20 | 2012-04-19 | ヤンセン バイオテツク，インコーポレーテツド | マイクロキャリア上での多能性幹細胞の培養 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2768720C (en) | 2009-07-20 | 2018-12-18 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| EP2456858B1 (en) | 2009-07-20 | 2018-08-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| SG177481A1 (en) | 2009-07-20 | 2012-02-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| PH12012500818A1 (en) * | 2009-10-29 | 2019-11-29 | Janssen Biotech Inc | Pluripotent stem cells |
| CA2784415C (en) | 2009-12-23 | 2019-06-18 | Jean Xu | Differentiation of human embryonic stem cells |
| SG181685A1 (en) * | 2009-12-23 | 2012-07-30 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells |
| SG183535A1 (en) | 2010-03-01 | 2012-10-30 | Janssen Biotech Inc | Methods for purifying cells derived from pluripotent stem cells |
| MX351515B (es) | 2010-05-12 | 2017-10-17 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
| CN103221536B (zh) | 2010-08-31 | 2016-08-31 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| ES2658146T3 (es) | 2010-08-31 | 2018-03-08 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas |
| AU2011296383B2 (en) | 2010-08-31 | 2016-03-10 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| ES2387359B1 (es) * | 2011-02-25 | 2013-08-01 | Consejo Superior De Investigaciones Científicas (Csic) | Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos |
| AU2012355698B2 (en) | 2011-12-22 | 2018-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
| US9434920B2 (en) | 2012-03-07 | 2016-09-06 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| MX358590B (es) | 2012-06-08 | 2018-08-24 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas. |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| AU2013370228B2 (en) | 2012-12-31 | 2018-10-18 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
| US10344264B2 (en) | 2012-12-31 | 2019-07-09 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
| SG10201707811XA (en) | 2012-12-31 | 2017-11-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
| SG10201810739VA (en) | 2014-05-16 | 2019-01-30 | Janssen Biotech Inc | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| CN109535158B (zh) * | 2016-04-26 | 2021-04-23 | 浙江工业大学 | 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用 |
| AU2020218366A1 (en) | 2019-02-08 | 2021-09-16 | Frequency Therapeutics, Inc. | Valproic acid compounds and Wnt agonists for treating ear disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
| BR9710648A (pt) | 1996-03-20 | 1999-08-17 | Lilly Co Eli | S¡ntese de indolilmaleimidas |
| SE9603283D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| EP1057484A4 (en) * | 1998-02-23 | 2002-11-20 | Sagami Chem Res | INHIBITORS OF CELL DEATH |
| AU4929999A (en) | 1998-07-30 | 2000-02-21 | Japan Tobacco Inc. | Disubstituted maleimide compounds and medicinal utilization thereof |
| DE69922526T2 (de) | 1998-10-08 | 2005-06-02 | Smithkline Beecham Plc, Brentford | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| HUP0301431A2 (hu) | 2000-07-27 | 2003-08-28 | F. Hoffmann-La Roche Ag. | 3-Indolil-4-fenil-1H-pirrol-2,5-dion-származékok, mint glikogén szintáz kináz-3béta inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| BRPI0115193B1 (pt) | 2000-11-07 | 2016-08-09 | Novartis Ag | derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende |
-
2003
- 2003-06-04 WO PCT/US2003/017569 patent/WO2003104222A1/en not_active Ceased
- 2003-06-04 US US10/454,069 patent/US6987110B2/en not_active Expired - Fee Related
- 2003-06-04 MX MXPA04012188A patent/MXPA04012188A/es unknown
- 2003-06-04 RU RU2004135382/04A patent/RU2004135382A/ru not_active Application Discontinuation
- 2003-06-04 CA CA002488602A patent/CA2488602A1/en not_active Abandoned
- 2003-06-04 BR BR0311821-5A patent/BR0311821A/pt not_active IP Right Cessation
- 2003-06-04 EP EP03734389A patent/EP1513830A1/en not_active Withdrawn
- 2003-06-04 CN CNA038184788A patent/CN1671694A/zh active Pending
- 2003-06-04 KR KR10-2004-7019678A patent/KR20050008787A/ko not_active Withdrawn
- 2003-06-04 AU AU2003238874A patent/AU2003238874A1/en not_active Abandoned
- 2003-06-04 JP JP2004511292A patent/JP2005531609A/ja not_active Withdrawn
-
2004
- 2004-12-02 IL IL16551504A patent/IL165515A0/xx unknown
- 2004-12-06 CR CR7606A patent/CR7606A/es unknown
- 2004-12-29 NO NO20045699A patent/NO20045699L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04012188A (es) | 2005-07-25 |
| WO2003104222A1 (en) | 2003-12-18 |
| BR0311821A (pt) | 2005-04-05 |
| CA2488602A1 (en) | 2003-12-18 |
| US6987110B2 (en) | 2006-01-17 |
| AU2003238874A1 (en) | 2003-12-22 |
| RU2004135382A (ru) | 2005-06-27 |
| CR7606A (es) | 2009-01-16 |
| KR20050008787A (ko) | 2005-01-21 |
| US20040059113A1 (en) | 2004-03-25 |
| IL165515A0 (en) | 2006-01-15 |
| CN1671694A (zh) | 2005-09-21 |
| JP2005531609A (ja) | 2005-10-20 |
| EP1513830A1 (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045699L (no) | Bisindolyl-maleimidderivater som kinaseinhibitorer | |
| NO20072115L (no) | Farmasoytiske forbindelser | |
| NO20061793L (no) | 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer | |
| WO2007149395A3 (en) | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer | |
| CA2111461A1 (en) | 3-Aminopiperidine Derivatives and Related Nitrogen Containing Heterocycles | |
| NO20060145L (no) | Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer | |
| DE69912581D1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
| SE0302232D0 (sv) | Novel Compounds | |
| EP1564213A4 (en) | IMIDAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| MY136959A (en) | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | |
| NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
| DE69706000D1 (de) | Indolderivat als 5-HT1A Antagonist und als Inhibitor der Serotonin-Wiederaufnahme | |
| NO20075409L (no) | Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater | |
| CA2368418A1 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders | |
| EA200300062A1 (ru) | Производные аминоалкилбензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции | |
| Biswas et al. | Synthesis of brominated novel N-heterocycles: New scaffolds for antimicrobial discovery | |
| MXPA04002570A (es) | Compuestos que inhiben la liberacion de citocinas inflamatorias. | |
| NO20081617L (no) | Metoder for fremstilling av Glutaminsyrederivater | |
| NO20050141L (no) | Prodrugs av imidazolderivater for anvendelse som protonpumpeinhibitorer ved behandlingen av f.eks. peptisk ulcus | |
| TW200420292A (en) | Benzofuran derivative | |
| WO2006110173A3 (en) | Novel compounds | |
| NO20050270L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
| AU2003281220A1 (en) | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors | |
| EA200401099A1 (ru) | Производные гетероциклического амида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |